leisure time -WSS

leisure time

author：explore 2025-09-06 03:32:45 - browse：79489

AstraZeneca said Friday it will buy up a group of early-stage gene therapies from Pfizer, bucking a trend of drugmakers axing programs and exiting a field that had once captured the imagination — and checkbooks — of many pharmaceutical executives.

AstraZeneca will pay Pfizer up to $1 billion plus royalties for the portfolio of treatments, none of which has entered clinical trials yet. The companies did not say how much it is paying upfront.

The moves come six months after Pfizer said it would stop much of its work on early-stage gene therapy programs, in which researchers try to deliver replacement genes encased in small, non-pathogenic bugs called adeno-associated viruses, or AAVs. Instead, it would focus on newer technologies, such as gene editing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Radiology is caught between AI's potential and concern for patients

WSS

The problems with dementia villages

STAT Summit: How researchers deal with rejection

STAT Summit: Ending the crisis of Black deaths in the U.S.

CMS should re

Roche to buy Carmot Therapeutics, developer of obesity drugs

In diabetes hearing, Sanders takes on a new foe: food makers

focus

leisure time

Wikipedia

How to save PrEP access — and even expand it

STAT Summit: Ending the crisis of Black deaths in the U.S.

Psychedelics group wrestles with new pharma identity

Patients' immediate access to test results puts radiologists in a bind

At least 13 dead in Texas as scorching temps continue

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Apple is now the first public company to be valued at $3 trillion

Cassava Sciences’ Alzheimer’s clinical trials should be halted

In Memoriam: Notable people who died in 2023

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

focus

STAT Readout: Friday, Oct. 20 biotech updates

AI models in health care face new federal disclosure requirements

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

AI models in health care face new federal disclosure requirements

What causes an itch? Researchers may have solved the mystery

Pregnancy discrimination could be enabled by AI

Wikipedia

explore

entertainment

hotspot